Dr. Mark Everett Schulte, MD

Dr. Schulte practices at Rheumatology Consultants Of Western New York in West Seneca, New York.

Dr. Schulte's NPI, 1093973471, was assigned on June 2, 2008. Dr. Schulte holds Ohio license 57.008831.

Dr. Schulte's primary practice is Rheumatology Consultants of Western New York, at 3615 Seneca St Suite F Suite F, West Seneca, NY 14224-3444. The practice phone is (716) 675-7376.

Dr. Schulte's primary practice is Rheumatology Consultants Of Western New York in West Seneca, New York. Dr. Schulte is also affiliated with Buffalo General Medical Center/Gates Vascular Institute. The medical group on file is Rheumatology Consultants of WNY. Dmand AI also links Dr. Schulte to 4 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Schulte practices, 6 sites in all. Vendor and product names are available with a free account.

Rheumatology is Dr. Schulte's primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dr. Schulte is board certified in rheumatology by the American Board of Internal Medicine. Dmand AI has Dr. Schulte's licenses on file in 2 states: Ohio and New York.

CMS data shows 30,612 Medicare services from Dr. Schulte across 14 procedure codes in 2024, for 209 Medicare patients. Medicare paid $670,730 for them. Every service was in an office.

CMS counts 209 Medicare patients who saw Dr. Schulte in 2024. The largest group is 65 to 74, with 94 patients. 75% of them have arthritis, and 75% have high blood pressure. 13% are also on Medicaid. Their average risk score is 1.38, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Schulte's median patient age at 69, with 70% women.

In 2024, Dr. Schulte wrote 2,912 Medicare Part D claims for 444 patients. 90% of them were for generic drugs. CMS names the drug for 2,719 of them, across 41 drugs with 11 or more claims each, at $1,557,116 in total drug cost. In 2023, CMS named 2,599 claims across 45 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Schulte for performance year 2024, reported as part of a group. Dr. Schulte accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 353 general payments to Dr. Schulte from 32 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 90% of the total. Janssen Pharmaceuticals, Inc paid the most, $887.